期刊
FRONTIERS IN ENDOCRINOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2021.721135
关键词
GLP-1 receptor agonists; endocrine; cardiovascular; neurological; cancer
资金
- NSFC [81770776, 81973378, 82073909]
- Cultivate Scientific Research Excellence Programs of Higher Education Institutions in Shanxi [2019KJ022]
- FSKSC
- 1331KSC
GLP-1 receptor agonists have been widely used in the treatment of type 2 diabetes due to their beneficial effects such as weight loss and protection of islet cells. Studies have shown that they have multiple biological effects on various tissues and organs, leading to potential applications in neuroprotection, cardiovascular protection, and metabolic regulation. The relationship between GLP-1RAs and tumorigenesis in patients with type 2 diabetes is also a subject of growing interest.
Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet beta cells, promotion of islet beta cell proliferation and minimal side effects. Studies have found that GLP-1R is widely distributed on pancreatic and other tissues and has multiple biological effects, such as reducing neuroinflammation, promoting nerve growth, improving heart function, suppressing appetite, delaying gastric emptying, regulating blood lipid metabolism and reducing fat deposition. Moreover, GLP-1RAs have neuroprotective, anti-infectious, cardiovascular protective, and metabolic regulatory effects, exhibiting good application prospects. Growing attention has been paid to the relationship between GLP-1RAs and tumorigenesis, development and prognosis in patient with T2DM. Here, we reviewed the therapeutic effects and possible mechanisms of action of GLP-1RAs in the nervous, cardiovascular, and endocrine systems and their correlation with metabolism, tumours and other diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据